SESSION XI: MANTLE CELL LYMPHOMA

Session Chairs: Timothy S. Fenske, MD, MS and Reem Karmali, MD, MS 

AI Models for Diagnosis and Prognostication in MCL | Eric Hsi, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

The Evolving Role of MRD in Mantle Cell Lymphoma | Timothy S. Fenske, MD, MS | Sarah Cannon Cancer Institute, San Antonio, Texas, USA

Post-BTKi Treatment in MCL | Krish Patel, MD | Sarah Cannon Research Institute, Nashville, Tennessee, USA

Treating High-Risk MCL | Reem Karmali, MD, MS | Northwestern University, Chicago, Illinois, USA

Oral Abstract | MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL) | Michael Wang, MD | MD Anderson Cancer Center, Houston, Texas, USA